Efficacy and Safety of Orelabrutinib Combined With Rituximab Versus Lenalidomide Combined With Rituximab in Patients With Relapsed/Refractory Marginal Zone Lymphoma

Efficacy and Safety of Orelabrutinib Combined with Rituximab versus Lenalidomide Combined with Rituximab in Patients with Relapsed/Refractory Marginal Zone Lymphoma

Trial Details

NCT ID
NCT06082102
Phase
PHASE3
Sponsor
Beijing InnoCare Pharma Tech Co., Ltd.
Status
RECRUITING
Cancer Type
Marginal Zone Lymphoma Lymphoma
Interventions
  • Orelabrutinib
  • Rituximab
  • Lenalidomide
Locations (sample)
  • Bengbu, Auhui, China|32.94083,117.36083
  • Beijing, Beijing Municipality, China|39.9075,116.39723
  • Beijing, Beijing Municipality, China|39.9075,116.39723
  • Guangzhou, Guangdong, China|23.11667,113.25
  • Guangzhou, Guangdong, China|23.11667,113.25

Key Eligibility Criteria

  • Age ≥ 18 years , either sex.
  • Histopathologically confirmed B-cell non-Hodgkin lymphoma MZL (splenic, nodal, or extra-nodal).
  • Prior systemic therapy including at least one anti-CD20 monoclonal antibody-containing regimen is required, with the following specifications:
  • For combination therapies: Minimum of 2 completed treatment cycles For anti-CD20 monotherapy: Minimum of 4 administered doses Progression during tr…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Marginal Zone Lymphoma Lymphoma Trials on Trialify →